Limits...
Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up

View Article: PubMed Central - PubMed

ABSTRACT

Polo-like kinase 1 (PLK1) is a serine-threonine kinase that plays a crucial role in the regulation of cell division. In addition, it acts as a modulator of the DNA damage response and as a novel factor in the maintenance of genome stability during DNA replication. The present study aimed to reveal the associations between PLK1 expression and clinicopathological features of patients with breast cancer (BC), particularly patient survival at 5-, 10- and 15-year follow-up. PLK1 expression was evaluated immunohistochemically in routine diagnostic tissue specimens from 83 patients treated radically for stage II BC. Kaplan-Meier analysis revealed a correlation between PLK1 overexpression and long-term survival. High PLK1 immunoreactivity was associated with shorter cancer-specific overall survival (CSOS) and disease-free survival (P=0.00001 and 0.00013, respectively). Multivariate analysis confirmed the negative prognostic significance of PLK1 overexpression for CSOS in all 83 patients (P=0.00030). Furthermore, analogous correlations were observed in both subgroups with and without nodal metastases (P=0.01400 and 0.01200, respectively). The present results indicate that PLK1 expression has a prognostic role in early BC. Immunohistochemical assessment of PLK1 reactivity may potentially become a qualifier for inclusion of PLK1 inhibitor therapy.

No MeSH data available.


Related in: MedlinePlus

PLK1 immunoreactivity and patient survival. High PLK1 immunoreactivity (IRS ≥8) was associated with shorter (A) CSOS (P=0.00001) and (B) DFS (P=0.00013). High PLK1 immunoreactivity was associated with shorter (C) CSOS (P=0.00110) and (D) DFS (P=0.00900) in patients without regional lymph node metastases. High PLK1 immunoreactivity was associated with shorter (E) CSOS (P=0.00900) and (F) DFS (P=0.03000) in patients with diagnosed nodal metastatic foci. PLK1, polo-like kinase 1; N, lymph nose metastasis; gr., group; CSOS, cancer-specific overall survival; DFS, disease-free survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998224&req=5

f2-ol-0-0-4890: PLK1 immunoreactivity and patient survival. High PLK1 immunoreactivity (IRS ≥8) was associated with shorter (A) CSOS (P=0.00001) and (B) DFS (P=0.00013). High PLK1 immunoreactivity was associated with shorter (C) CSOS (P=0.00110) and (D) DFS (P=0.00900) in patients without regional lymph node metastases. High PLK1 immunoreactivity was associated with shorter (E) CSOS (P=0.00900) and (F) DFS (P=0.03000) in patients with diagnosed nodal metastatic foci. PLK1, polo-like kinase 1; N, lymph nose metastasis; gr., group; CSOS, cancer-specific overall survival; DFS, disease-free survival.

Mentions: Kaplan-Meier analysis confirmed the correlation of PLK1 overexpression with long-term survival, as high PLK1 immunoreactivity (IRS ≥8) was associated with shorter CSOS and DFS (P=0.00001 and 0.00013, respectively) (Fig. 2A and B). Additionally, high PLK1 immunoreactivity was correlated with shorter CSOS and DFS in patients without local lymph node metastases (P=0.00110 and 0.00900, respectively) (Fig. 2C and D) and in patients with diagnosed nodal metastatic foci (P=0.00900 and 0.03000, respectively) (Fig. 2E and F).


Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up
PLK1 immunoreactivity and patient survival. High PLK1 immunoreactivity (IRS ≥8) was associated with shorter (A) CSOS (P=0.00001) and (B) DFS (P=0.00013). High PLK1 immunoreactivity was associated with shorter (C) CSOS (P=0.00110) and (D) DFS (P=0.00900) in patients without regional lymph node metastases. High PLK1 immunoreactivity was associated with shorter (E) CSOS (P=0.00900) and (F) DFS (P=0.03000) in patients with diagnosed nodal metastatic foci. PLK1, polo-like kinase 1; N, lymph nose metastasis; gr., group; CSOS, cancer-specific overall survival; DFS, disease-free survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998224&req=5

f2-ol-0-0-4890: PLK1 immunoreactivity and patient survival. High PLK1 immunoreactivity (IRS ≥8) was associated with shorter (A) CSOS (P=0.00001) and (B) DFS (P=0.00013). High PLK1 immunoreactivity was associated with shorter (C) CSOS (P=0.00110) and (D) DFS (P=0.00900) in patients without regional lymph node metastases. High PLK1 immunoreactivity was associated with shorter (E) CSOS (P=0.00900) and (F) DFS (P=0.03000) in patients with diagnosed nodal metastatic foci. PLK1, polo-like kinase 1; N, lymph nose metastasis; gr., group; CSOS, cancer-specific overall survival; DFS, disease-free survival.
Mentions: Kaplan-Meier analysis confirmed the correlation of PLK1 overexpression with long-term survival, as high PLK1 immunoreactivity (IRS ≥8) was associated with shorter CSOS and DFS (P=0.00001 and 0.00013, respectively) (Fig. 2A and B). Additionally, high PLK1 immunoreactivity was correlated with shorter CSOS and DFS in patients without local lymph node metastases (P=0.00110 and 0.00900, respectively) (Fig. 2C and D) and in patients with diagnosed nodal metastatic foci (P=0.00900 and 0.03000, respectively) (Fig. 2E and F).

View Article: PubMed Central - PubMed

ABSTRACT

Polo-like kinase 1 (PLK1) is a serine-threonine kinase that plays a crucial role in the regulation of cell division. In addition, it acts as a modulator of the DNA damage response and as a novel factor in the maintenance of genome stability during DNA replication. The present study aimed to reveal the associations between PLK1 expression and clinicopathological features of patients with breast cancer (BC), particularly patient survival at 5-, 10- and 15-year follow-up. PLK1 expression was evaluated immunohistochemically in routine diagnostic tissue specimens from 83 patients treated radically for stage II BC. Kaplan-Meier analysis revealed a correlation between PLK1 overexpression and long-term survival. High PLK1 immunoreactivity was associated with shorter cancer-specific overall survival (CSOS) and disease-free survival (P=0.00001 and 0.00013, respectively). Multivariate analysis confirmed the negative prognostic significance of PLK1 overexpression for CSOS in all 83 patients (P=0.00030). Furthermore, analogous correlations were observed in both subgroups with and without nodal metastases (P=0.01400 and 0.01200, respectively). The present results indicate that PLK1 expression has a prognostic role in early BC. Immunohistochemical assessment of PLK1 reactivity may potentially become a qualifier for inclusion of PLK1 inhibitor therapy.

No MeSH data available.


Related in: MedlinePlus